RSV Prevention May Reduce Long-Term Asthma Risk, New Research Suggests
Table of Contents
New research indicates that preventing Respiratory Syncytial Virus (RSV) infection in infants could substantially reduce their risk of developing asthma later in life. A study led by researchers at VIB-UGent and Ghent University [https://www.vib.be/news/preventing-rsv-may-prevent-asthma] demonstrates a link between early RSV infection and lasting changes in the immune system that contribute to asthma development. This finding underscores the importance of widespread RSV prevention efforts, including maternal vaccination and newborn immunization.
How RSV Can Increase Asthma Risk
RSV is a common respiratory virus that typically causes mild, cold-like symptoms. However, for infants and young children, it can lead to severe illness, including bronchiolitis and pneumonia. The new research reveals that RSV infection in newborns can trigger a cascade of immune responses that alter the development of the immune system.
Specifically, the study found that RSV infection leads to an increase in a type of immune cell that promotes airway inflammation. This inflammation makes the lungs more susceptible to developing asthma, particularly in individuals with a genetic predisposition. The researchers observed that allergen-specific antibodies passed from parents to newborns can further increase sensitivity, making children even more vulnerable.
Experimental Evidence: Preventing RSV Prevents Asthma
The research team conducted experiments on animal models, demonstrating that protecting newborns from RSV wholly prevented the observed immune system shifts.Crucially, this protection also prevented the development of asthma.
“A key part of the work showed that protecting newborns from RSV in experimental models prevented thes immune system shifts altogether. Consequently,asthma did not develop,” the study authors note. [https://www.vib.be/news/preventing-rsv-may-prevent-asthma]
The possibility for Long-Term Respiratory Health
Professor Hamida Hammad (VIB-UGent), co-senior author of the study, emphasizes the broader implications of these findings.”With RSV prevention now becoming widely accessible, we have an opportunity to improve long-term respiratory health, not just prevent RSV hospitalizations,” she states. [https://www.vib.be/news/preventing-rsv-may-prevent-asthma]
Currently, two primary methods for RSV prevention are being implemented in many countries:
* Maternal Vaccination: Administering an RSV vaccine to pregnant individuals during the third trimester of pregnancy. the FDA approved the first RSV vaccine for pregnant people in August 2023. [https://www.fda.gov/news-events/press-announcements/fda-approves-first-rsv-vaccine-pregnant-people-protect-babies]
* Passive Immunization: Providing newborns with a long-acting antibody (nirsevimab, marketed as Beyfortus) that offers immediate protection against RSV. [https://www.cdc.gov/rsv/index.html]
Despite the proven effectiveness of these tools in preventing severe RSV illness, uptake has been inconsistent.
A Call to Action for Public health
professor Lambrecht highlights the need for coordinated action. “This is a moment were policy, science, and pediatricians can come together,” he says. “If preventing RSV infection also reduces asthma risk, the benefits for families and health systems could be enormous.”
Key Takeaways:
* RSV infection in infancy can alter the immune system, increasing the risk of asthma.
* Preventing RSV infection in newborns can prevent these immune system changes and reduce asthma risk.
* Maternal vaccination and newborn immunization are effective strategies for RSV prevention.
* Increased uptake of RSV prevention measures is crucial for improving long-term respiratory health.
Frequently Asked Questions (FAQ)
Q: Is RSV always serious for babies?
A: No, many babies experience mild, cold-like symptoms from RSV.However, for some infants – particularly those with underlying health conditions or premature babies – RSV can lead to severe illness requiring hospitalization. [https://www.cdc.gov/rsv/index.html]
Q: How effective are RSV vaccines and immunizations?
A: Clinical trials have shown that both maternal RSV vaccines and nirsevimab are highly effective at preventing severe RSV illness and hospitalizations. [https://www.cdc.gov/rsv/index.html]
Q: If my baby had RSV last season, is it too late to benefit from prevention?
A: This research suggests that early prevention is most effective in altering the immune system’s trajectory. However, continuing to protect your child from future RSV infections is still crucial for overall respiratory health. Consult with your pediatrician for personalized advice.
This research was